Lundbeck Foundation wants stronger biotech businesses in Denmark, but this doesn't rule out international growth
A managing partner at Lundbeckfonden Emerge would like to see more biotech businesses growing bigger and staying in Denmark, but this doesn't mean they can't also go public in the US.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY DANIEL PEDERSEN
When Danish biotech companies reach a certain size, the growth is usually supplemented by an acquisition offer from a bigger firm, often from abroad. There's nothing wrong with this model, says Christian Elling, managing partner at Lundbeckfonden Emerge, even if he would prefer to see a more of them stay in Denmark for longer, growing domestically.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
IO Biotech prepares for IPO in the US
For subscribers
Lundbeck Foundation buys stake in asset manager
For subscribers
Ascendis Pharma aims for USD 400m from share issue
For subscribers
.jpg&w=384&q=75)
